[Prolactinoma: from quest of pregnancy to delivery].

[1]  P. García-Pavía,et al.  No clinically significant valvular regurgitation in long‐term cabergoline treatment for prolactinoma , 2012, Clinical endocrinology.

[2]  Victor M Montori,et al.  Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[3]  P. Bernard,et al.  Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women , 2010, Clinical endocrinology.

[4]  O. Dekkers,et al.  Update in prolactinomas. , 2010, The Netherlands journal of medicine.

[5]  P. Caron.  [Prevention of thyroid disorders in pregnant women]. , 2009, Journal de gynecologie, obstetrique et biologie de la reproduction.

[6]  A. Colao.  Pituitary tumours: the prolactinoma. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[7]  B. Delemer.  [Prolactinomas: diagnosis and treatment]. , 2009, Presse medicale.

[8]  W. Ludlam.  Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study , 2008 .

[9]  T. Méas,et al.  Cabergoline treatment of pregnant women with macroprolactinomas , 2007, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[10]  J. Schlechte.  Long-term management of prolactinomas. , 2007, The Journal of clinical endocrinology and metabolism.

[11]  P. Touraine,et al.  Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy. , 2007, Annales d'endocrinologie.

[12]  S. Ouzounian,et al.  Hypothyroïdie : du désir de grossesse à l'accouchement , 2007 .

[13]  B. Delemer,et al.  Diagnosis and management of hyperprolactinemia: expert consensus - French Society of Endocrinology. , 2007, Annales d'endocrinologie.

[14]  M. Molitch.  Prolactin-secreting tumors: what’s new? , 2006, Expert review of anticancer therapy.

[15]  P. Cappabianca,et al.  Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas , 2006, Clinical endocrinology.

[16]  A. Colao,et al.  Advances in the treatment of prolactinomas. , 2006, Endocrine reviews.

[17]  P. Krupp,et al.  Bromocriptine in pregnancy: Safety aspects , 1987, Klinische Wochenschrift.

[18]  M. Bronstein.  Prolactinomas and Pregnancy , 2005, Pituitary.

[19]  J. Sadoul.  Adénomes à prolactine et grossesse , 2004 .

[20]  Patrick Santens,et al.  Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease , 2004, The Lancet.

[21]  J. Tyrrell,et al.  Successful Treatment of a Large Macroprolactinoma with Cabergoline During Pregnancy , 2001, Pituitary.

[22]  M. Molitch.  Pituitary tumors and pregnancy. , 2003, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[23]  M. Bonati,et al.  Pregnancy outcome after cabergoline treatment in early weeks of gestation. , 2002, Reproductive toxicology.

[24]  J. Bonneville.  [When the pituitary swells up a little]. , 2002, Journal de radiologie.

[25]  J. Pruvo,et al.  [Pituitary adenomas and pregnancy: morphological MRI features]. , 2002, Journal de radiologie.

[26]  E. Giolo,et al.  Pregnancy in Hyperprolactinemic Infertile Women Treated with Vaginal Bromocriptine: Report of Two Cases and Review of the Literature , 2001, Gynecologic and Obstetric Investigation.

[27]  A. Colao,et al.  Growth-hormone and prolactin excess , 1998, The Lancet.

[28]  M. Longo,et al.  Reproductive toxicity of cabergoline in mice, rats, and rabbits. , 1996, Reproductive toxicology.

[29]  L. Musatti,et al.  Pregnancy outcome after treatment with the ergot derivative, cabergoline. , 1996, Reproductive toxicology.

[30]  J. Webster.  A Comparative Review of the Tolerability Profiles of Dopamine Agonists in the Treatment of Hyperprolactinaemia and Inhibition of Lactation , 1996 .

[31]  A. Fitton,et al.  Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. , 1995, Drugs.

[32]  A. Elster,et al.  Size and shape of the pituitary gland during pregnancy and post partum: measurement with MR imaging. , 1991, Radiology.

[33]  B. Scheithauer,et al.  The Pituitary Gland in Pregnancy: A Clinicopathologic and Immunohistochemical Study of 69 Cases , 1990 .

[34]  F. Peillon,et al.  Resistance to bromocriptine in prolactinomas. , 1989, The Journal of clinical endocrinology and metabolism.

[35]  R. Ziegler,et al.  Retroperitoneal fibrosis in a patient with macroprolactinoma treated with bromocriptine. , 1989, BMJ.

[36]  G. Elizondo,et al.  Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging. , 1988, American Journal of Medicine.

[37]  U. Holmgren,et al.  Women with prolactinoma--effect of pregnancy and lactation on serum prolactin and on tumour growth. , 1986, Acta endocrinologica.

[38]  M. Molitch.  Pregnancy and the hyperprolactinemic woman. , 1985, The New England journal of medicine.

[39]  S. Asa,et al.  Prolactin cells in the human pituitary. A quantitative immunocytochemical analysis. , 1982, Archives of pathology & laboratory medicine.

[40]  C. Gemzell,et al.  Outcome of pregnancy in women with pituitary adenoma. , 1979, Fertility and sterility.